Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:14664145rdf:typepubmed:Citationlld:pubmed
pubmed-article:14664145lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:14664145lifeskim:mentionsumls-concept:C0033325lld:lifeskim
pubmed-article:14664145lifeskim:mentionsumls-concept:C0029925lld:lifeskim
pubmed-article:14664145lifeskim:mentionsumls-concept:C0243161lld:lifeskim
pubmed-article:14664145lifeskim:mentionsumls-concept:C1513712lld:lifeskim
pubmed-article:14664145lifeskim:mentionsumls-concept:C1441616lld:lifeskim
pubmed-article:14664145lifeskim:mentionsumls-concept:C0440743lld:lifeskim
pubmed-article:14664145pubmed:issue5lld:pubmed
pubmed-article:14664145pubmed:dateCreated2003-12-10lld:pubmed
pubmed-article:14664145pubmed:abstractTextThe aim of the study was to investigate the prognostic value of morphometrical features and expression of receptors to progesterone in malignant epithelial ovarian tumours. Surgical biopsy materials of 92 patients with serous and mucinous ovarian cancer were investigated. Tissues stained by hematoxilin and eosin were studied. Morphometry was performed with computer program Axio Vision 3.0. Immunohistochemical characteristics were evaluated with monoclonal progesterone antibodies. It was found that cytomorphometrical features vary in ovarian cancer with different histological structures and the level of differentiation of tumour, and can be used as prognostic factors. We revealed correlation between cytomorphometric factors (carcinoma cell area, total nuclear area, roundness of cell) and risk of recurrences and metastatic spread. In serous cancers presence of progesterone receptors is a favorable factor of prognosis and, as a rule, associates with a high degree of tumour differentiation. In this group of patients 3-year survival reached almost 100% indicating the efficiency of hormonotherapy and chemotherapy.lld:pubmed
pubmed-article:14664145pubmed:languageruslld:pubmed
pubmed-article:14664145pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14664145pubmed:citationSubsetIMlld:pubmed
pubmed-article:14664145pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14664145pubmed:statusMEDLINElld:pubmed
pubmed-article:14664145pubmed:issn0004-1955lld:pubmed
pubmed-article:14664145pubmed:authorpubmed-author:KolosovA EAElld:pubmed
pubmed-article:14664145pubmed:authorpubmed-author:NovichkovE...lld:pubmed
pubmed-article:14664145pubmed:issnTypePrintlld:pubmed
pubmed-article:14664145pubmed:volume65lld:pubmed
pubmed-article:14664145pubmed:ownerNLMlld:pubmed
pubmed-article:14664145pubmed:authorsCompleteYlld:pubmed
pubmed-article:14664145pubmed:pagination29-32lld:pubmed
pubmed-article:14664145pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:14664145pubmed:meshHeadingpubmed-meshheading:14664145...lld:pubmed
pubmed-article:14664145pubmed:meshHeadingpubmed-meshheading:14664145...lld:pubmed
pubmed-article:14664145pubmed:meshHeadingpubmed-meshheading:14664145...lld:pubmed
pubmed-article:14664145pubmed:meshHeadingpubmed-meshheading:14664145...lld:pubmed
pubmed-article:14664145pubmed:meshHeadingpubmed-meshheading:14664145...lld:pubmed
pubmed-article:14664145pubmed:meshHeadingpubmed-meshheading:14664145...lld:pubmed
pubmed-article:14664145pubmed:meshHeadingpubmed-meshheading:14664145...lld:pubmed
pubmed-article:14664145pubmed:meshHeadingpubmed-meshheading:14664145...lld:pubmed
pubmed-article:14664145pubmed:meshHeadingpubmed-meshheading:14664145...lld:pubmed
pubmed-article:14664145pubmed:meshHeadingpubmed-meshheading:14664145...lld:pubmed
pubmed-article:14664145pubmed:meshHeadingpubmed-meshheading:14664145...lld:pubmed
pubmed-article:14664145pubmed:articleTitle[Morphometrical and immunohistochemical criteria of prognosis in patients with serous and mucinous ovarian carcinoma].lld:pubmed
pubmed-article:14664145pubmed:affiliationKirov State Medical Academy, Kirov.lld:pubmed
pubmed-article:14664145pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:14664145pubmed:publicationTypeEnglish Abstractlld:pubmed